Diabetology, Vol. 6, Pages 161: Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes Diabetology doi: 10.3390/diabetology6120161 Authors: Scott

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist

ORLANDO, Fla. — Eli Lilly’s new chief dealmaker is planning to spend its GLP-1 cash in an “aggressive” but responsible manner. Last month, Lilly’s president

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion

The systematic review and meta-analysis of 48 trials involving 94,245 individuals show little or no effect of GLP-1 RA treatment on the risk for obesity-related

SAN DIEGO–(BUSINESS WIRE)–SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, today announced the launch of two studies to

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai

Molson Coors Beverage Company (NYSE:TAP) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On November 21, Piper Sandler lowered

On Nov. 19, Pfizer CFO Dave Denton said at the Jefferies Global Healthcare Conference that the large pharma was still looking for an oral small

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light. Medscape Medical News

College students may seek you out over winter break wanting to start a GLP-1. Medscape Medical News

Food Funct., 2026, Accepted ManuscriptDOI: 10.1039/D5FO03164H, Paper Jiaomei Li, Hao Wang, Jiekai Yang, Yicheng Wang, Guo Jia, Jiaojiao Gu1,3-Diacylglycerol (1,3-DAG) is a dietary lipid with

Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related cancers, new research suggests.

The rise in the use of GLP-1 weight-loss drugs across the U.S. is shifting not only scales, but also how Americans are spending their time

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D)

(NaturalNews) A large-scale study of over 1.2 million patients found that more than half (58%) of those who stop GLP-1 weight-loss drugs like Wegovy and

Federal Trade Commission crackdown on company selling GLP-1 is a reminder of the dangers consumers face when purchasing trending treatments online

GLP-1 weight loss medications like Ozempic, Mounjaro, and Wegovy are rapidly growing in popularity. In fact, research from KFF last year found that about one

Sometimes it seems like the winter holidays are all about food—Grandma’s famous pie at Thanksgiving, cocoa and cookies with the neighbors, a full spread at

What You Should Know:  – Castlight Health and Noom have formed a strategic partnership to embed Noom’s preventive health and weight management programs directly into

Patients and employers are feeling the pain of increased health premiums. wildpixel/iStock via Getty Images Plus Health insurance premiums in the U.S. significantly increased between

A new WHO guideline on GLP-1s and recent efforts to reduce the drugs’ costs now and going forward are unlikely to change US obesity practice

Biotech Soars On Potential ‘Best-In-Class’ Obesity Drug  Investor’s Business Daily Structure’s Obesity Pill Delivers Weight-Loss ‘Homerun’ in Study  Bloomberg.com Structure reports promising weight loss outcomes with obesity

GLP-1 support from the grocery store? The research gets interesting

Why Pfizer and Roche look like top choices for investors in the war to tip the scales.

Structure Therapeutics said Monday that its investigational GLP-1 pill led to substantial weight loss in two mid-stage trials, but patients also experienced high rates of

More than 1.5 million Brits now take GLP-1 medications

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! With STAT reporting

Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, researchers aren’t giving up yet.

Quick Read Abbott Laboratories (ABT) grew revenue 6.9% with medical devices up 14.8% to $5.45B. Abbott reaffirmed guidance for 7.5-8.0% organic growth. Eli Lilly (LLY)

Shares of The Magnum Ice Cream Company (LSE:MICC) started trading today (8 December), making them eligible for an ISA portfolio.  This came after the ice